粪菌移植对原发性高血压的作用及肠道菌群恢复的内在机制:随机、盲法、安慰剂对照研究方案
高血压控制率不佳,亟需新型有效干预。本研究为多中心、随机、安慰剂对照、盲法临床试验,纳入120例1级高血压患者,随机1:1口服粪菌移植胶囊或安慰剂胶囊,于第1、7、14天给药,随访至第90天,主要结局为基线与第30天诊室收缩压变化,并探索肠道菌群与代谢组学机制。
要点
- 多中心随机盲法安慰剂对照试验,纳入120例1级高血压患者,干预3个月。
- 主要结局为基线与第30天诊室收缩压变化,次要结局含血压、血管功能及菌群代谢组学。
- 研究基于既往动物与人类研究提示的肠道菌群与血压升高的因果关系。
核心结论
- 本研究旨在将既往关于肠道菌群参与高血压发病机制的研究推向临床转化,探索粪菌移植治疗高血压的潜力。
- 将通过宏基因组测序与代谢组学分析等途径,探究特定微生物或其后生元在改善血压中的作用。
研究设计与样本
- 多中心、随机、安慰剂对照、盲法临床试验,纳入120例1级高血压患者,干预3个月。
- 所有入组患者按1:1比例随机分配至口服粪菌移植胶囊组或安慰剂胶囊组,于第1天、第7天、第14天服用,并于第30天、第60天、第90天随访。
主要发现
- 主要结局为基线与第30天诊室收缩压的变化。
- 主要次要结局包括诊室及24小时动态血压监测的收缩压与舒张压变化、踝臂指数与脉搏波速度评估、粪便微生物组成与功能谱分析、粪便与血清代谢组谱分析、血糖血脂及体重指数变化,以及不良事件评估作为安全性指标。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypertension is currently the leading modifiable cause of global morbidity and mortality, leading to substantial health and financial burdens. Although multiple studies of management models and innovative therapeutic strategies for hypertension have been conducted, there are still gaps in the field, with a poor control rate reflecting a lack of novel, effective, clinically translated medication or intervention options. Recent animal and human studies repeatedly confirmed a link between the microbiota and hypertension. Of note is our previous study establishing a cause-and-effect relationship between the gut microbiota and blood pressure elevation. A hypothesis of gut microbiota intervention for treating hypertension is thus postulated, and fecal microbiota transplantation (FMT) from healthy donors was performed. METHODS: A multicenter, randomized, placebo-controlled, blinded clinical trial will be performed in 120 grade 1 hypertensive patients for 3 months. All recruited patients will be randomly assigned in a 1:1 ratio to take oral FMT capsules or placebo capsules on day 1, day 7, and day 14 and will be followed up on day 30, day 60, and day 90. The primary outcome is the change in office systolic blood pressure from baseline to day 30. The main secondary outcomes are BP indicators, including changes in systolic and diastolic blood pressure from office and 24-h ambulatory blood pressure monitoring; assessments of ankle-branchial index and pulse wave velocity; profiling of fecal microbial composition and function; profiling of fecal and serum metabolome; changes in levels of blood glucose, blood lipids, and body mass index; and assessment of adverse events as a measure of safety. DISCUSSION: Expanding upon our previous research on the role of the gut microbiota in the pathogenesis of hypertension, this study serves as a clinical translation advancement and explores the potential of fecal microbiota transplantation for treating hypertension. The underlying mechanisms, particularly the roles of specific microorganisms or their postbiotics in blood pressure amelioration, will also be investigated via multiple approaches, such as metagenomic sequencing and metabolomic profiling. TRIAL REGISTRATION: ClinicalTrials.gov NCT04406129 . Registered on May 28, 2020.
引用
- Fan L, Ren J, Chen Y, et al. Effect of fecal microbiota transplantation on primary hypertension and the underlying mechanism of gut microbiome restoration: protocol of a randomized, blinded, placebo-controlled study. Trials. 2022. PMID: 35209934. doi:10.1186/s13063-022-06086-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。